7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cancer Testis Antigen, NOL4, Is an Immunogenic Antigen Specifically Expressed in Small-Cell Lung Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To identify cancer/testis (CT) antigens and immunogenic proteins, immunoscreening of testicular and small-cell lung cancer cell line NCI-H889 cDNA libraries was performed using serum obtained from a small-cell lung cancer (SCLC) patient. We obtained 113 positive cDNA clones comprised of 74 different genes, designated KP-SCLC-1 through KP-SCLC-74. Of these genes, 59 genes were found to be related to cancers by EMBASE analysis. Three of these antigens, including KP-SCLC-29 (NOL4), KP-SCLC-59 (CCDC83), and KP-SCLC-69 (KIF20B), were CT antigens. RT-PCR and western blot analysis showed that NOL4 was frequently present in small-cell lung cancer cell lines (8/9, 8/9). In addition, NOL4 mRNA was weakly, or at a low frequency, or not detected in various cancer cell lines. Our results reveal that NOL4 was expressed at protein levels in small-cell lung cancer tissues (10/10) but not detected in lung adenocarcinoma and squamous cell carcinoma by immunohistochemical analysis. Serological response to NOL4 was also evaluated by western blot assay using NOL4 recombinant protein. A humoral response against NOL4 proteins was detected in 75% (33/44) of small-cell lung cancer patients and in 65% (13/20) of healthy donors by a serological western blot assay. These data suggest that NOL4 is a specific target that may be useful for diagnosis and immunotherapy in SCLC.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

          Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered mouse models, appear to be converging on a new model of SCLC subtypes defined by differential expression of four key transcription regulators: achaete-scute homologue 1 (ASCL1; also known as ASH1), neurogenic differentiation factor 1 (NeuroD1), yes-associated protein 1 (YAP1) and POU class 2 homeobox 3 (POU2F3). In this Perspective, we review and synthesize these recent lines of evidence and propose a working nomenclature for SCLC subtypes defined by relative expression of these four factors. Defining the unique therapeutic vulnerabilities of these subtypes of SCLC should help to focus and accelerate therapeutic research, leading to rationally targeted approaches that may ultimately improve clinical outcomes for patients with this disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Small cell lung cancer: where do we go from here?

            Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately 14% of all lung cancers. In the United States, approximately 31,000 patients are diagnosed annually with SCLC. Despite numerous clinical trials, including at least 40 phase 3 trials since the 1970s, systemic treatment for patients with SCLC has not changed significantly in the past several decades. Consequently, the 5-year survival rate remains low at <7% overall, and most patients survive for only 1 year or less after diagnosis. Unlike nonsmall cell lung cancer (NSCLC), in which major advances have been made using targeted therapies, there are still no approved targeted drugs for SCLC. Significant barriers to progress in SCLC include 1) a lack of early detection modalities, 2) limited tumor tissue for translational research (eg, molecular profiling of DNA, RNA, and/or protein alterations) because of small diagnostic biopsies and the rare use of surgical resection in standard treatment, and 3) rapid disease progression with poor understanding of the mechanisms contributing to therapeutic resistance. In this report, the authors review the current state of SCLC treatment, recent advances in current understanding of the underlying disease biology, and opportunities to advance translational research and therapeutic approaches for patients with SCLC.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cancer/testis (CT) antigens: potential targets for immunotherapy.

              Cancer/testis (CT) antigens are protein antigens with normal expression restricted to adult testicular germ cells, and yet are aberrantly activated and expressed in a proportion of various types of human cancer. At least a subset of this group of antigens has been found to elicit spontaneous humoral and cell-mediated immune responses in cancer patients, raising the possibility that these antigens could be cancer vaccine targets. More than 100 CT antigen genes have been reported in the literature, with approximately 30 being members of multigene families on the X chromosome, so-called CT-X genes. Most CT-X genes are expressed at the spermatogonia stage of spermatogenesis, and their functions are mostly unknown. In cancer, the frequency of CT antigen expression is highly variable among different tumor types, but is more often expressed in high-grade late-stage cases in general. Cancer vaccine trials based on CT antigens MAGE-A3 and NY-ESO-1 are currently ongoing, and these antigens may also play a role in antigen-specific adoptive T-cell transfer and in the immunomodulation approach of cancer therapy.
                Bookmark

                Author and article information

                Journal
                Curr Oncol
                Curr Oncol
                curroncol
                Current Oncology
                MDPI
                1198-0052
                1718-7729
                20 May 2021
                June 2021
                : 28
                : 3
                : 1927-1937
                Affiliations
                [1 ]Department of Biochemistry, School of Medicine, Pusan National University, Beomeo-ri, Mulgeum-eup, Yangsan 50612, Korea; gbigtree@ 123456naver.com (Y.-R.K.); haga88@ 123456naver.com (D.-W.K.)
                [2 ]Department of Internal Medicine, Pusan National University Hospital, 1-10 Ami-dong, Seo-gu, Busan 49241, Korea; uk303@ 123456hanmail.net (K.-U.K.); leemk@ 123456pusan.ac.kr (M.-K.L.)
                [3 ]Department of Pathology, School of Medicine, Pusan National University, Beomeo-ri, Mulgeum-eup, Yangsan 50612, Korea; 4unii@ 123456hanmail.net (J.-H.L.); donghshin@ 123456chol.com (D.-H.S.)
                [4 ]Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan 50612, Korea; jhchung7942@ 123456gmail.com
                [5 ]Department of Thoracic Surgery, Pusan National University Hospital, 1-10 Ami-dong, Seo-gu, Busan 49241, Korea; domini@ 123456pusan.ac.kr
                [6 ]Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Korea; rmshin@ 123456pusan.ac.kr
                Author notes
                [* ]Correspondence: sangyull@ 123456pusan.ac.kr ; Tel.: +82-51-510-8084
                Author information
                https://orcid.org/0000-0002-4449-1468
                Article
                curroncol-28-00179
                10.3390/curroncol28030179
                8161805
                34065612
                30668dae-429c-4a7f-b699-cbd56ac1a88a
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 18 March 2021
                : 09 May 2021
                Categories
                Article

                Oncology & Radiotherapy
                kp-sclc-29,nol4,cancer/testis antigen,small-cell lung cancer,serex
                Oncology & Radiotherapy
                kp-sclc-29, nol4, cancer/testis antigen, small-cell lung cancer, serex

                Comments

                Comment on this article